Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 4OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Pancreatic Neoplasms 108Breast Neoplasms 72Carcinoma, Non-Small-Cell Lung 38Triple Negative Breast Neoplasms 29Squamous Cell Carcinoma of Head and Neck 18Neoplasm Metastasis 14Esophageal Squamous Cell Carcinoma 14Neoplasms 12Head and Neck Neoplasms 11Lung Neoplasms 10Stomach Neoplasms 9Gallbladder Neoplasms 8Cholangiocarcinoma 8Adenocarcinoma 8Melanoma 7Esophageal Neoplasms 7Biliary Tract Neoplasms 7Sarcoma 6Ovarian Neoplasms 5Inflammatory Breast Neoplasms 5Small Cell Lung Carcinoma 4Recurrence 4Pancreatic Adenocarcinoma 4Carcinoma, Ductal, Breast 4Uveal Melanoma 3Uterine Cervical Neoplasms 3Tongue Neoplasms 3Thymoma 3Pancreatic Diseases 3Nasopharyngeal Carcinoma 3

Interventions

pembrolizumab 36Gemcitabine 29Nivolumab 20Cisplatin 19atezolizumab 15avelumab 14Docetaxel 13Carboplatin 10enfortumab vedotin 9durvalumab 9Magnetic Resonance Spectroscopy 9Ipilimumab 8Paclitaxel 7Pemetrexed 6toripalimab 5cabozantinib 5Fluorodeoxyglucose F18 5sacituzumab govitecan 4cabazitaxel 4Taxes 4vinflunine 3tremelimumab 3pemigatinib 3X-Rays 3Standard of Care 3Specimen Handling 3Radiotherapy 3Mitomycin 3Immunotherapy 3Immunoglobulin G 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Carcinoma, Transitional Cell × 130-nm albumin-bound paclitaxel × Clear all
NCT02887248 2023-12-05

Nab-paclitaxel Plus Gemcitabine as First-line Therapy for Cisplatin-ineligible or Cisplatin-incurable Advanced Urothelial Carcinoma

SCRI Development Innovations, LLC

Phase 2 Terminated
3 enrolled 9 charts
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡